Mediwound reports first quarter 2024 financial results and provides company update

Nexobrid® interest surges; $5 million in q1 2024 revenue, with $24 million forecast for the year manufacturing facility on target for completion by mid-2024 escharex® phase iii study to launch 2h 2024 company set to join russell 3000® index conference call today, may 29 at 8:30am eastern time yavne, israel, may 29, 2024 (globe newswire) -- mediwound ltd. (nasdaq: mdwd), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended march 31, 2024, and provided a corporate update.
MDWD Ratings Summary
MDWD Quant Ranking